Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the intention-to-treat population

From: A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial

  Placebo (n = 11) SB010 (n = 12) p-value
Gender [M/F] 7/4 8/4 n.s.
Age [years] 58.9 ± 6.9
59 (54–64)
67.4 ± 7.9
70 (65–73)
<  0.05
Height [cm] 172 ± 8
170 (167–176)
171 ± 13
172 (160–178)
n.s.
Weight [kg] 76.9 ± 21.6
73.5 (61–92.4)
75.5 ± 15.4
71.8 (66–82.5)
n.s.
BMI [kg/m2] 25.9 ± 6.4
25.5 (20.4–29.8)
25.6 ± 2.7
25.2 (23.4–28.0)
n.s.
FEV1 [l] post-bd 1.57 (1.17–1.78) 1.16 (0.98–1.72) n.s.
FEV1 [% pred.] post-bd 51.5 ± 13
51 (40.1–60.9)
47.5 ± 10.2
46.4 (39–55.5)
n.s.
Reversibility (post-BD – pre-BD) [l] 0.17 (0.13–0.37) 0.13 (0.04–0.23) n.s.#
GOLD stages [II/III] 6/5 4/8 n.s.
Current/Ex Smokers 8/3 7/5 n.s.
Packyears 46.1 ± 20.4
42.1 (30–70)
53.6 ± 29.9
45 (30.8–83.5)
n.s.
LAMA-containing regimen [%] 63.6 58.3 n.s.
LABA-containing regimen [%] 45.5 50.0 n.s.
ICS-containing treatment regimen [%] 54.6 41.7 n.s.
IgEtot. [U/ml] 75 (11–991.4) 22.6 (9.5–51.3) n.s.
IgEtot. > 100 [%] 45.5 16.7 n.s.
FeNO [ppb] 22.0 (11.7–28.0) 13.7 (8.5–21.7) n.s.
Blood eosinophils [G/l] 0.26 ± 0.11
0.24 (0.16–0.32)
0.28 ± 0.11
0.28 (0.21–0.36)
n.s.
Blood eosinophils [%] 3.5 ± 1.5
3.0 (2.2–4.9)
4.0 ± 1.6
4.1 (3.6–5.0)
n.s.
Sputum eosinophils [×  103/ml] 86 (30–279) 245 (105–552) n.s.
Sputum eosinophils [% non-squamous cells] 4.6 (3.3–10.1) 6.1 (4.2–7.9) n.s.
  1. Data are displayed as mean ± SD in the upper row, median (25% – 75%) in the lower row. For variables not normally distributed in at least one group, data are displayed as median (25% percentile – 75% percentile). Categorical variables are displayed as absolute numbers or percentage as indicated. P values were calculated using the exact Wilcoxon two-sample test for continuous variables and Fisher’s exact test for categorical variables As tests for normality of residuals were based on a small sample size, the t test was also performed for each continuous variable yielding the same result with regard to statistical significance except for reversibility. FeNO: Fraction of exhaled nitric oxide (at 50 ml/s flow-rate); LABA Long acting beta-2-receptor agonist, LAMA Long acting muscarinic acetylcholine-receptor antagonist, ppb Parts per billion, ICS Inhaled corticosteroid, n.s Not significant. # p < 0.05 tested with two-sample t test